 Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
| Descriptor ID |
D061026
|
| MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.035.588 D23.050.301.264.894.790 D23.101.100.110.588 D23.101.100.894.790
|
| Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- Programmed Cell Death 1 Protein
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- PD1 Receptor
- Receptor, PD1
- Antigens, CD279
- CD279 Antigens
- CD279 Antigen
- Antigen, CD279
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Programmed Cell Death 1 Receptor [D23.050.301.264.035.588]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Programmed Cell Death 1 Receptor [D23.101.100.110.588]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 | | 2004 | 0 | 3 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 3 | 3 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 2 | 4 | | 2015 | 2 | 3 | 5 | | 2016 | 3 | 6 | 9 | | 2017 | 5 | 6 | 11 | | 2018 | 6 | 4 | 10 | | 2019 | 7 | 16 | 23 | | 2020 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Tierney JF, Vogle A, Finnerty B, Zarnegar R, Ghai R, Gattuso P, Fahey TJ, Keutgen XM. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma. J Surg Res. 2020 12; 256:90-95.
-
Choi JW, Withers SS, Chang H, Spanier JA, De La Trinidad VL, Panesar H, Fife BT, Sciammas R, Sparger EE, Moore PF, Kent MS, Rebhun RB, McSorley SJ. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 2020; 15(7):e0235518.
-
Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020 08 15; 26(16):4171-4173.
-
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684.
-
Gajewski TF. Strategies to overcome resistance to PD-1 inhibitors. Clin Adv Hematol Oncol. 2020 May; 18(5):270-272.
-
Miller CH, Klawon DEJ, Zeng S, Lee V, Socci ND, Savage PA. Eomes identifies thymic precursors of self-specific memory-phenotype CD8+ T cells. Nat Immunol. 2020 05; 21(5):567-577.
-
Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210.
-
Macatangay BJC, Gandhi RT, Jones RB, Mcmahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR. T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS. 2020 01 01; 34(1):15-24.
-
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
-
Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. Cancer. 2020 03 15; 126(6):1166-1174.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|